STENOCARE – Deadline soon to subscribe for new shares at DKK 0.50 each
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“Stenocare” or the "Company") began on January 07 the subscription period for investors to subscribe for new shares at a discounted price of DKK 0.50 each. This is a time limited offer until January 20, 2025 – however some banks, including Nordnet, have a shorter deadline on Monday January 13. Shareholders and new investors interested in this offer should check the deadline with their bank.
Stenocare has announced a time limited offer to subscribe for new shares in the Company at a discounted price of DKK 0.50 per share. The Company is seeking to raise between DKK 9.1 million and DKK 20.2 million to execute the STENOCARE 3.0 strategy.
All the details are available on the investor homepage: https://stenocare.com/share-issue-2025/
How the offer works?
This offer is available until January 20, 2025, at 5.00 P.M. CET, and there are following ways to access the discounted price:
- Existing shareholders have received a notification/email from their bank, where their Stenocare shares are kept. Follow the instructions from the bank to use your subscription rights to purchase the new shares.
- New investors should use the online subscription form in their bank or use the official Subscription Form to instruct their bank to subscribe for the offer.
To read the official announcement of the conditional rights issue: https://stenocare.com/investor-relations/announcements/3B051C92836EB553/
Who are Stenocare?
Stenocare is a Danish company that has specialised in trading with prescription-based medical cannabis products. The Company has sales activities in 6 different countries with medical cannabis products approved for sales by the local medicine agencies. Stenocare has just launched a new and innovative product, called ASTRUM 10-10, that has the potential to revolutionise the medical cannabis industry. This new patented product has been approved for sales in Germany, Australia and Norway.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.
www.stenocare.com www.stenocare.dk www.stenocare.se